Phase 3 failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed to meet its primary endpoint in the treatment of unresectable metastatic bladder cancer.
Specifically, the study was investigating the therapy’s efficacy in adult patients in whom over 25% of their tumour cells express PD-L1, or in patients receiving the combo regardless of PD-L1 expression.
